SAN DIEGO & WATERTOWN, Mass. — Artis BioSolutions announced it has established new synthetic DNA manufacturing capabilities in the Boston area, expanding its North American footprint and strengthening supply chain resilience for advanced therapies.
The new capability integrates Syngoi Technologies’ proprietary enzymatic DNA production platform into Artis’ existing operations, including its advanced therapy development and GMP manufacturing facility in Watertown, Mass. The company said the expansion is designed to deliver scalable, efficient, and reliable solutions for global customers developing next-generation genetic medicines.
“Artis was founded to more effectively provide platforms and capabilities that drug developers require to bring next-generation medicines to patients,” said Brian Neel, CEO of Artis. “Establishing U.S.-based synthetic DNA manufacturing is a pivotal step in the evolution of the Artis platform and reinforces our mission to integrate specialized technologies — from synthetic DNA through GMP manufacturing — into a seamless, end-to-end offering. By offering Syngoi Technologies at our U.S. site, we are delivering a much needed capability to our customers focused on early development through clinical manufacturing while strengthening our global operational resilience.”
The expansion allows Artis to operate production hubs in both the United States and Europe, enabling dual sourcing for customers. The company said this approach reduces lead times and logistics costs while mitigating risks associated with relying on a single geographic region.
The Boston-area location also places Artis closer to key biotechnology partners and customers, supporting faster collaboration and responsiveness in a major life sciences hub.
“From our beginning, Syngoi set out to reimagine how clinical-grade synthetic DNA is produced and delivered for advanced therapy applications,” said Julen Oyarzabal, CSO of Syngoi.
“Establishing this new U.S.-based manufacturing site is a natural extension of that mission. Operating in the premier biotechnology innovation ecosystem of the greater Boston area, allows us to respond more rapidly to regional customer demand while maintaining the continuity and technical excellence of our European operations,” said José Vicente Pons Andreu, CEO of Syngoi.
Syngoi’s enzymatic platform enables rapid production of clinical-grade synthetic DNA through a cell-free cGMP process. By replacing traditional plasmid-based bacterial fermentation with an enzymatic approach, the technology is designed to deliver higher purity material with shorter production timelines.
The company said the platform can also generate customized DNA constructs tailored to specific programs, supporting a wide range of applications in advanced therapy development. (Source: IANS)
